Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18680940 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | May 2024 | April 2025 | Allow | 10 | 1 | 0 | No | No |
| 18663549 | METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A VEGF INHIBITOR FOR TREATING SOLID TUMORS | May 2024 | May 2025 | Allow | 12 | 1 | 0 | No | No |
| 18603567 | WILD TYPE KIT INHIBITORS | March 2024 | December 2024 | Allow | 9 | 2 | 1 | No | No |
| 18429094 | PYRAZOLO[1,5-a]PYRIDO[4,3-e]PYRIMIDINE-3-CARBOXYLIC ACIDS AS CK2 INHIBITORS | January 2024 | May 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18545047 | IMIDAZO[1,2-C]PYRIDO[3,4-E]PYRIMIDINE-2-CARBOXYLIC ACIDS AS CK2 INHIBITORS | December 2023 | April 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18495457 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | October 2023 | September 2024 | Allow | 11 | 2 | 1 | No | No |
| 18217287 | PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST AND SOLVENTS CAPABLE OF DISSOLVING HIGH AMOUNTS OF THE DRUG | June 2023 | September 2024 | Allow | 14 | 1 | 1 | No | No |
| 18209165 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | June 2023 | April 2024 | Allow | 10 | 0 | 1 | No | No |
| 18202525 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | May 2023 | June 2025 | Abandon | 25 | 2 | 1 | No | No |
| 18315533 | AT2R ANTAGONISTS AND USES THEREOF | May 2023 | June 2024 | Allow | 13 | 0 | 1 | Yes | No |
| 18130641 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | April 2023 | July 2024 | Allow | 15 | 1 | 1 | No | No |
| 18181138 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | March 2023 | September 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17912142 | CRYSTAL FORM OF AROMATIC VINYL DERIVATIVES, AND PREPARATION METHOD THEREFOR AND USE THEREOF | September 2022 | June 2025 | Allow | 33 | 1 | 0 | No | No |
| 17941860 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | September 2022 | June 2024 | Allow | 21 | 1 | 0 | No | No |
| 17930578 | Formulations of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile | September 2022 | December 2024 | Allow | 27 | 1 | 1 | No | No |
| 17790831 | METHODS FOR PRACTICAL SYNTHESIS OF DEUTERATED AMINO ACIDS | July 2022 | January 2025 | Allow | 31 | 1 | 1 | No | No |
| 17830858 | COMPOSITIONS AND METHODS COMPRISING DEOXY-PENTITOLS | June 2022 | November 2024 | Allow | 30 | 1 | 1 | No | No |
| 17667883 | 2-(Het)aryl-substituted fused bicyclic heterocycle derivatives as pesticides | February 2022 | July 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17631876 | Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders | January 2022 | December 2024 | Allow | 34 | 1 | 1 | No | No |
| 17587374 | CRYSTAL FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE | January 2022 | June 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17597550 | L-Y-METHYLENEGLUTAMINE COMPOUNDS AND METHODS OF USE | January 2022 | January 2025 | Allow | 37 | 0 | 0 | Yes | No |
| 17524050 | METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A VEGF INHIBITOR FOR TREATING SOLID TUMORS | November 2021 | February 2024 | Allow | 27 | 0 | 1 | No | No |
| 17604729 | CRYSTALLINE FORMS AND METHODS OF PRODUCING CRYSTALLINE FORMS OF A COMPOUND | October 2021 | February 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17502468 | DILUENTS FOR COMPOSITIONS OF CANNABINOIDS AND USES THEREOF | October 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17602848 | COMPOSITION AND METHODS FOR RECTAL DELIVERY OF 4-AAPA AND 5-ASA COMPOUNDS | October 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17602480 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THEREOF | October 2021 | March 2025 | Allow | 41 | 1 | 1 | No | No |
| 17602533 | TRIPLE COMBINATION OF AN ERK1/2 INHIBITOR WITH A BRAF INHIBITOR AND AN EGFR INHIBITOR FOR USE IN THE TREATMENT OF BRAFv6ooE COLORECTAL CANCER | October 2021 | May 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17494450 | STABILIZED LIQUID FORMULATION OF LEVOTHYROXINE | October 2021 | February 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17601586 | PHARMACEUTICAL COMBINATION OF PIMOZIDE AND METHOTREXATE AND USE THEREOF | October 2021 | May 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17601123 | MACITENTAN FOR USE IN TREATING PORTOPULMONARY HYPERTENSION | October 2021 | April 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17441775 | METHOD FOR PREPARING WATER-SOLUBLE ASTAXANTHIN COMPLEX AND AQUEOUS SOLUTION OF ASTAXANTHIN PREPARED THEREBY | September 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17593113 | POLYMORPHS OF A CARDIAC TROPONIN ACTIVATOR | September 2021 | February 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17468051 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | September 2021 | May 2025 | Allow | 44 | 1 | 1 | No | No |
| 17434535 | INHIBITORS OF NGAL PROTEIN | August 2021 | February 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17429603 | CRYSTALLINE FORMS OF AN RSK INHIBITOR | August 2021 | March 2025 | Allow | 43 | 1 | 0 | No | No |
| 17386379 | LYMPHATIC MEDIATED TRANSPORT-BASED TRIGLYCERIDE PRODRUG, AND PREPARATION METHOD THEREFOR | July 2021 | January 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17424870 | USE OF IONIZATION RADIATION SOURCE IN PREPARATION OF POROUS CRYSTALLINE MATERIAL | July 2021 | March 2025 | Allow | 44 | 1 | 1 | No | No |
| 17423389 | ENPP1 Inhibitors and Methods of Modulating Immune Response | July 2021 | November 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17416910 | CRYSTALLINE AND SALT FORMS OF AN ORGANIC COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | June 2021 | January 2025 | Allow | 43 | 1 | 0 | No | No |
| 17415110 | Pharmaceutical process for the preparation of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-((R)-S-methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl}-1H-pyrrolo[2,3-b] pyridine and intermediates | June 2021 | March 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17300404 | Photochromic xanthene fluorophores and their utility in live-cell imaging beyond the diffraction limit | June 2021 | March 2025 | Allow | 45 | 1 | 1 | No | No |
| 17348079 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | June 2021 | May 2025 | Allow | 47 | 1 | 1 | No | No |
| 17413738 | SYNTHETIC I2 IMIDAZOLINE RECEPTOR LIGANDS FOR PREVENTION OR TREATMENT OF HUMAN BRAIN DISORDERS | June 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17311975 | S3QELS TO PROTECT AGAINST INTESTINAL PERMEABILITY | June 2021 | February 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17311673 | Hypoxia Targeting Compositions and Combinations Thereof with a PARP Inhibitor and Methods of Use Thereof | June 2021 | January 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17299602 | METHOD FOR PRODUCING FLUOROVINYL AMIDE COMPOUND | June 2021 | December 2024 | Allow | 42 | 0 | 1 | No | No |
| 17298047 | CARBOXYLIC ACID DERIVATIVES | May 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17298088 | L-PROLINE SULFONAMIDE DERIVATIVES COMPRISING PYRAZOLO[4,3- E]TETRAZOLO[4,5-B][1,2,4]TRIAZINE SYSTEM, METHOD OF MANUFACTURING THEREOF, USES THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | May 2021 | December 2024 | Allow | 43 | 1 | 1 | No | No |
| 17297329 | PHARMACEUTICAL BIODISSOLVABLE GELS FOR DRUG DELIVERY | May 2021 | July 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17296462 | COMBINATION TREATMENT OF HIV INFECTIONS | May 2021 | January 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17325355 | METHOD OF TREATING CANCER PREFERABLY CHARACTERIZED BY EXPRESSION OF A FUSION PROTEIN COMPRISING A MEMBER OF THE E-TWENTY-SIX FAMILY BY ADMINISTERING AN AGENT THAT INHIBITS THE SYNTHESIS AND/OR ACTIVITY OF CORTISOL | May 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17293874 | SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF | May 2021 | October 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17293592 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | May 2021 | October 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17315011 | THERAPEUTIC REGIMENS FOR TREATMENT OF CANCER USING ERIBULIN AND SELECTIVE CDK4/6 INHIBITOR COMBINATIONS | May 2021 | September 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17285413 | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING METABOLIC DISEASES AND/OR A CLINICAL CONDITION THEREOF | April 2021 | January 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17285152 | Aqueous 1,2-Benzisothiazolin-3-One Concentrates | April 2021 | January 2025 | Allow | 45 | 2 | 1 | No | No |
| 17278385 | PROCESS FOR PREPARING A NOVEL PHENICOL ANTIBACTERIAL AGENT | March 2021 | July 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17164583 | POLYMORPH OF LATREPIRDINE DIHYDROCHLORIDE | February 2021 | July 2024 | Allow | 41 | 2 | 0 | No | No |
| 17255560 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | December 2020 | October 2024 | Allow | 46 | 1 | 1 | No | No |
| 16967337 | CONTINUOUS PROCESS FOR THE PREPARATION OF TRAZODONE | August 2020 | October 2024 | Allow | 51 | 1 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner ISMAIL, REHANA works in Art Unit 1625 and has examined 56 patent applications in our dataset. With an allowance rate of 57.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner ISMAIL, REHANA's allowance rate of 57.1% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ISMAIL, REHANA receive 0.68 office actions before reaching final disposition. This places the examiner in the 6% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by ISMAIL, REHANA is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +50.0% benefit to allowance rate for applications examined by ISMAIL, REHANA. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 97% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 99% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 25.0% are granted (fully or in part). This grant rate is in the 15% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.